187 related articles for article (PubMed ID: 33474679)
21. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
22. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
23. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
24. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
[TBL] [Abstract][Full Text] [Related]
25. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
Kim S; Han J; Shin I; Kil WH; Lee JE; Nam SJ
Exp Mol Med; 2012 Aug; 44(8):473-82. PubMed ID: 22627808
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
Huang CS; Yang Y; Kwong A; Chen SC; Tseng LM; Liu MC; Shen K; Wang S; Ng TY; Feng Y; Sun G; Yan IR; Shao Z
Breast Cancer Res Treat; 2021 Jun; 187(3):759-768. PubMed ID: 33860389
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.
Li G; Guo J; Shen BQ; Yadav DB; Sliwkowski MX; Crocker LM; Lacap JA; Phillips GDL
Mol Cancer Ther; 2018 Jul; 17(7):1441-1453. PubMed ID: 29695635
[TBL] [Abstract][Full Text] [Related]
28. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
[TBL] [Abstract][Full Text] [Related]
29. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
30. Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis.
Nersesian S; Williams R; Newsted D; Shah K; Young S; Evans PA; Allingham JS; Craig AW
Sci Rep; 2018 Nov; 8(1):17243. PubMed ID: 30467396
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells.
Vadlamudi R; Adam L; Tseng B; Costa L; Kumar R
Cancer Res; 1999 Jun; 59(12):2843-6. PubMed ID: 10383144
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis.
Zhang J; Li J; Zhu C; Song Y; Xia F; Ma X
Drug Des Devel Ther; 2017; 11():3235-3244. PubMed ID: 29180848
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M; Tanner M; Köninki K; Isola J
Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
[TBL] [Abstract][Full Text] [Related]
34. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
[TBL] [Abstract][Full Text] [Related]
36. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
Montemurro F; Ellis P; Anton A; Wuerstlein R; Delaloge S; Bonneterre J; Quenel-Tueux N; Linn SC; Irahara N; Donica M; Lindegger N; Barrios CH
Eur J Cancer; 2019 Mar; 109():92-102. PubMed ID: 30708264
[TBL] [Abstract][Full Text] [Related]
37. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
[TBL] [Abstract][Full Text] [Related]
38. The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.
Asrani K; Keri RA; Galisteo R; Brown SA; Morgan SJ; Ghosh A; Tran NL; Winkles JA
Mol Cancer Res; 2013 Apr; 11(4):393-404. PubMed ID: 23378579
[TBL] [Abstract][Full Text] [Related]
39. T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways.
Endo Y; Shen Y; Youssef LA; Mohan N; Wu WJ
MAbs; 2018 Oct; 10(7):1003-1017. PubMed ID: 30130447
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort.
Daniels B; Kiely BE; Tang M; Houssami N; Lord SJ; Pearson SA
Breast; 2021 Aug; 58():106-112. PubMed ID: 33992964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
